Posts tagged Alzheimer's Association International Conference
ProMIS releases clinical results at Alzheimer’s conference

ProMIS Neurosciences (TSX:PMN) released results in two presentations of its recent therapeutic developments at the Alzheimer’s Association International Conference in Toronto.

“Our results presented at the AAIC meeting indicate that multiple monoclonal antibodies (mAbs) directed against five novel AD targets are viable therapeutic candidates, as they showed selective binding to the oligomeric forms of Amyloid beta, with little or no binding to Amyloid beta monomer,” CSO, Neil Cashman, said in a statement.

Read More
Anavex reports Phase 2a efficacy data in AD

Anavex Life Sciences (NASDAQ:AVXL) announced efficacy data through 31 weeks from the ongoing ANAVEX 2-73 Phase 2a study in mild-to-moderate Alzheimer’s patients at the Alzheimer’s Association International Conference in Toronto.

Read More
Anavex presents safety data in AD

Anavex Life Sciences (NASDAQ:AVXL) presented safety data for its ANAVEX 2-73 drug candidate at the Alzheimer’s Association International Conference 2016 in Toronto.

Data presented in a poster highlights the evaluation of a maximum tolerated dose of ANAVEX 2-73 as primary endpoint of the Phase 2a study in mild-to-moderate Alzheimer’s patients, as well as additional clinical safety data and positive unexpected therapeutic response events, such as improved mood, improved social engagement and increased independent activities through 31 weeks.

Read More